The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.
May 13th 2024
In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.
Genetic Analysis Identifies New Targets in Triple-Negative Breast Cancer
Patients with triple-negative breast cancer who have residual disease after receiving neoadjuvant chemotherapy have a series of genetic alterations that are clinically targetable and may warrant further study.
Evolution of Targeted Therapy: GIST Experience Points the Way to Defining Third-Line Treatment
November 19th 2012Targeted antineoplastic therapy based on the presence of a well-defined molecular target should be recognized as a standard-of-care approach in an increasing number of clinical settings.